GLB-001

GluBio Therapeutics Inc. · Phase 1 active Small molecule

At a glance

Generic name	GLB-001
Also known as	GLB-C183-A-2
Sponsor	GluBio Therapeutics Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes (PHASE1)
A Study of GLB-001 in Patients With Myeloid Malignancies (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GLB-001 CI brief — competitive landscape report
GLB-001 updates RSS · CI watch RSS
GluBio Therapeutics Inc. portfolio CI